What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Surgery
His primary areas of study are Internal medicine, Surgery, Oncology, Melanoma and GiST.
His Internal medicine study frequently draws connections between adjacent fields such as Gastroenterology.
His Surgery study incorporates themes from Clinical trial, Combination therapy and Sarcoma.
His work focuses on many connections between Oncology and other disciplines, such as Cancer, that overlap with his field of interest in Pathology.
He combines subjects such as Survival rate, Trametinib and Sentinel node with his study of Melanoma.
His Ipilimumab study combines topics from a wide range of disciplines, such as Pembrolizumab and Nivolumab.
His most cited work include:
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (4552 citations)
- Nivolumab in previously untreated melanoma without BRAF mutation. (3334 citations)
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial (2107 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Internal medicine, Oncology, Melanoma, Surgery and GiST.
He regularly links together related areas like Gastroenterology in his Internal medicine studies.
The Oncology study which covers Dabrafenib that intersects with Trametinib.
In his work, Sentinel node is strongly intertwined with Biopsy, which is a subfield of Melanoma.
His Surgery research is multidisciplinary, relying on both Radiology, Sarcoma and Hazard ratio.
His Ipilimumab study which covers Nivolumab that intersects with Pembrolizumab.
He most often published in these fields:
- Internal medicine (52.11%)
- Oncology (38.53%)
- Melanoma (28.26%)
What were the highlights of his more recent work (between 2019-2021)?
- Internal medicine (52.11%)
- Oncology (38.53%)
- Melanoma (28.26%)
In recent papers he was focusing on the following fields of study:
Piotr Rutkowski mainly focuses on Internal medicine, Oncology, Melanoma, Sarcoma and Radiation therapy.
His study on Internal medicine is mostly dedicated to connecting different topics, such as Gastroenterology.
His Oncology research is multidisciplinary, incorporating perspectives in Concomitant, GiST and Dabrafenib.
His studies deal with areas such as Sentinel lymph node and Cancer, Immunotherapy as well as Melanoma.
His biological study spans a wide range of topics, including Surgical oncology, Surgery, Leiomyosarcoma and Disease.
As a part of the same scientific study, Piotr Rutkowski usually deals with the Pembrolizumab, concentrating on Nivolumab and frequently concerns with Ipilimumab.
Between 2019 and 2021, his most popular works were:
- Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. (79 citations)
- Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial (78 citations)
- Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. (43 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Surgery
The scientist’s investigation covers issues in Internal medicine, Oncology, Hazard ratio, Clinical trial and Randomized controlled trial.
The Internal medicine study combines topics in areas such as Gastroenterology and Melanoma.
The various areas that Piotr Rutkowski examines in his Melanoma study include Jurkat cells and Immune privilege.
His research integrates issues of Soft tissue sarcoma, Radiation therapy and Hypofractionated Radiotherapy in his study of Oncology.
His work deals with themes such as Proportional hazards model and Performance status, which intersect with Hazard ratio.
His Randomized controlled trial study combines topics in areas such as Adverse effect, Progression-free survival and Ipilimumab.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
